Navigation Links
Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy
Date:6/19/2009

TROMS0, Norway and SEOUL, Korea, June 19 /PRNewswire/ -- The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced the signing of a collaborative agreement to test lead compounds LTX-315 and GV1001 as a combination therapy for the treatment of cancer.

According to Lytix Biopharma CEO Gunnar Saelid and KAEL-GemVax CEO Jay Sangjae Kim, "We are delighted to announce this joint venture to test a combination of two very interesting experimental drugs. In preclinical models, LTX-315 has demonstrated the ability to effect necrotic killing of cancer cells. Simulatenously it also causes the release of warning signals from the stressed and dying cells that trigger activation of the immune system. On the other hand GV1001, a telomerase peptide vaccine in phase III trials, is one of the best documented anti-cancer vaccines currently in development, with a potentially broad utility against a range of cancer types.

"There is a strong scientific rationale for combining these agents, providing a local inflammatory response combined with specific vaccination - these two novel agents should have the potential to function as an efficient immunotherapy for the treatment of cancer," says Mr Jon Amund Eriksen, Director of Product Development, Oncology at Lytix Biopharma. Mr Eriksen is also one of the key persons, together with Professor Gustav Gaudernack, at the Norwegian Radium Hospital involved in the development of GV1001.

Speaking on behalf of their respective companies, business development spokespeople Anders Fugelli (Lytix Biopharma) and Michelle Kyunghee Kim (KAEL-GemVax) comment, "KAEL-GemVax and Lytix Biopharma will both contribute scientific and regulatory, as well as financial, support to the planned study in patients, sharing the results for use in the future clinical development programs for each proprietary agent. Lytix Biopharma will be responsible for
'/>"/>

SOURCE Lytix Biopharma AS
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lytix Closes USD 10.4 Million Funding Round
2. ZyGEM and Advalytix Partner to Produce Innovative DNA Extraction Products
3. Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.
4. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
5. PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million
6. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
7. Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
8. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
9. Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
10. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
11. DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Richardson, Texas (PRWEB) October 20, 2014 ... today announced that a team from Iowa State University ... * design contest. Using a Convey HC-2ex, the team’s ... than 14 times faster than the second place finisher. ... academic world embarked upon the month long challenge, using ...
(Date:10/20/2014)... PureTech , a science and ... problems, announced today the closing of a $55 ... Invesco Perpetual, a $120 Billion group of funds. ... existing pipeline forward and to advance new healthcare ... creativity to really go for the big ideas ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
(Date:10/19/2014)... report "Chocolate, Cocoa Beans, Lecithin, Sugar and Vanilla Market ... (2011 - 2016)," analyzes the chocolate market by ... market drivers, restraints, and opportunities for the chocolate market ... chocolate market is expected to grow from $83.2 billion ... CAGR of 2.7% from 2011 to 2016. , Get ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... N.J., Sept. 17 Medarex, Inc.,(Nasdaq: MEDX ) ... the UBS,Global Life Sciences Conference at 4:30 p.m. Eastern ... webcast live and will be available in,the Investor Relations ... archived edition of the presentation will be available following ...
... Former Chair Of Psychology Department At Harvard University,Joins Panel Of ... ... Neurological Testing Company, BERKELEY, Calif., Sept. 17 NeuroFocus, ... for marketing,research, announced that professor Stephen Kosslyn, Ph.D. has joined ...
... LOUIS, Sept. 17 Sigma-Aldrich Corporation,(Nasdaq: SIAL ) ... Sciences,Conference on Wednesday, September 24th at 8:30 AM ET ... may listen via live audio broadcast over the,Internet available ... to access this file. For the webcast on, http://ir.sigmaaldrich.com ...
Cached Biology Technology:Neurofocus Appoints Stephen Kosslyn to Its Advisory Board 2
(Date:10/17/2014)... . To date, ... overdoses, doctors are often limited to supportive therapy such as ... combination of drugs involved. So what can be done if ... ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences ... question. "The task was to develop an agent that could ...
(Date:10/16/2014)... synthesis of recent research findings to inform their management ... states. , The Ecology and Management of Moist ... of the Relevant Biophysical Science and Implications for Future ... U.S. Forest Service,s Pacific Northwest Research Station, is a ... synthesis of the large body of scientific information on ...
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3New report synthesizes best available science on management of moist mixed-conifer forests 2New perspectives for development of an RSV vaccine 2
... A great deal of science learning takes place ... for example, and through TV programs, books, and online ... new from the National Research Council, recommends ways museum ... foster science learning for people of all ages, backgrounds, ...
... An Australian method for assessing the environmental impact of ... agencies worldwide. Aspects of the ,ecological risk assessment, ... Ecuador, and the Western and Central Pacific, and by ... The method was developed in research led by Dr ...
... Two junior researchers from Ludwig-Maximilians-Universitt (LMU) in ... the European Research Council (ERC). Professor Jens Michaelis, ... David Vhringer, Institute of Immunology, shall receive grants ... five years. With its Starting Grant, the ERC ...
Cached Biology News:World interest in Australian fishery impact test 2LMU Munich researchers highly endowed with EU funding 2
Designed for use with any of the Agencourt kits in tube format....
... (4,6-diamidine-2-phenylindole, dihydrochloride) is a fluorescent ... blue in color. The bright ... to red fluorochromes such as ... R-Phycoerythrin. DAPI can be used ...
... cytochrome P450 (CYP450) metabolite postulated to play ... cerebral vasculature. In rat cerebral microvessels, 20-HETE ... vasoconstriction. 20-HETE is excreted mainly as the ... (20-40 pg/ml in human urine) is about ...
... APAgene kits are designed to rapidly ... using our patented APA Technology. APAgene provides ... competitive price. All necessary ingredients are provided ... can be used for gap filling, localized ...
Biology Products: